Apolipoprotein A1 (apoA1) is considered as a potential treatment to exploit the athero-protective effects of high-density lipoprotein cholesterol (HDL-C), but solid
A doctor says he wishes his patients could see what he sees as they look at themselves in a mirror
Analog Indulgence
Rhabdomyolysis can cause extreme muscle pain, liver damage, kidney failure and death
Women are less likely than men to be treated with cholesterol-lowering statins – or get them prescribed at guideline-recommended intensity levels when they do, according to a new study that also looked at reasons behind the discrepancies
Expert Perspective: If the patient is considered intermediate risk but there are ≥1 risk-enhancing factors or a high CAC score as in #8 and #9, you can discuss higher intensity statin as an option
Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol Diabetes Obes Metab
Introduction
Commercial sales; Lancet Careers ISSUE 10170, P407-415, February 02, 2019
The cholesterol hypothesis holds that high blood cholesterol is a major risk factor for atherosclerosis cardiovascular disease (ASCVD) and lowering cholesterol levels will reduce risk for ASCVD
Statins are cholesterol-lowering medications
Statins are administered as first-line agents to lower plasma LDL cholesterol (LDL-C) levels []
Lipitor is for adults and children over 10 whose cholesterol does not come down enough with exercise and a low-fat diet alone
Benefits from statin therapy for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) are supported by high-quality evidence from randomised controlled trials (RCT)
It reduces levels of triglycerides and “bad” LDL cholesterol in the blood and increases levels of “good” HDL cholesterol
These medications have certainly helped many density lipoprotein cholesterol (LDL-C) with high-intensity statin therapy or maximally tolerated statin therapy
LIPITOR is used: to reduce the risk of: heart attack, stroke, certain types of heart surgery and chest pain in adults who do not have heart disease but have other multiple risk factors for heart disease
The current 2019 European Society of Cardiology (ESC) guidelines for the management of dyslipidaemias suggest a target LDL-C of 55 mg/dL (1